BMS builds in ‘in vivo’ cell therapy with $1.5bn Orbital buy
Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is developing RNA medicines that can ‘reprogramme’ immune cells in the body and direct them to treat diseases. Its pipeline is headed by OTX-201,…